# Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
**SUMMARY:**
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 16 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
**DATES:**
Approval is withdrawn as of June 15, 2020.
**FOR FURTHER INFORMATION CONTACT:**
Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137.
**SUPPLEMENTARY INFORMATION:**
The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.
| Application No. | Drug | Applicant |
| --- | --- | --- |
| NDA 011529 | Parafon Forte DSC (chlorzoxazone), Caplets, 500 milligrams (mg) | Janssen Pharmaceuticals, Inc., 1000 Route 202 South, P.O. Box 300, Raritan, NJ 08869. |
| NDA 018029 | Ritalin-SR (methylphenidate hydrochloride (HCl)) Extended-Release Tablets, 20 mg | Novartis Pharmaceuticals Corp., 1 Health Plaza, East Hanover, NJ 07936. |
| NDA 018082 | Depakene (valproic acid) Oral Solution, 250 mg/5 milliliter (mL) | AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064. |
| NDA 019579 | Terazol 7 (terconazole) Vaginal Cream, 0.4% | Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton Rd., Titusville, NJ 08560. |
| NDA 020119 | Vumon (teniposide) Injection, 10 mg/mL | HQ Specialty Pharma, 120 Route 17 North, Paramus, NJ 07652. |
| NDA 020388 | Navelbine (vinorelbine tartrate) Injection, Equivalent to (EQ) 10 mg/mL base | Pierre Fabre Medicament c/o Pierre Fabre Pharmaceuticals, Inc., 8 Campus Dr., Suite 202, Parsippany, NJ 07054. |
| NDA 020741 | Prandin (repaglinide) Tablets, 0.5 mg, 1.0 mg, and 2.0 mg | Gemini Laboratories, LLC, 400 Crossing Blvd., 5th Floor, Bridgewater, NJ 08807. |
| NDA 020920 | Natrecor (nesiritide) Injection, 1.5 mg/vial | Scios, LLC, 1125 Trenton-Harbourton Rd., Titusville, NJ 08560. |
| NDA 021001 | Axert (almotriptan malate) Tablets, EQ 6.25 mg base and EQ 12.5 mg base | Janssen Pharmaceuticals, Inc. |
| NDA 021203 | Tricor (fenofibrate) Tablets, 54 mg and 160 mg | AbbVie Inc. |
| NDA 021543 | Striant (testosterone buccal system) Extended-Release Tablets, 30 mg | Auxilium Pharmaceuticals, Inc., 1400 Atwater Dr., Malvern, PA 19355. |
| NDA 021604 | Children's ElixSure IB (ibuprofen) Oral Suspension, 100mg/5 mL | Moberg Pharma North America LLC, 7 East Frederick Place, Suite 100, Cedar Knolls, NJ 07927. |
| NDA 021611 | Opana (oxymorphone HCl) Tablets, 5mg and 10mg | Endo Pharmaceuticals, Inc., 1400 Atwater Dr., Malvern, PA 19355. |
| NDA 022321 | Embeda (morphine sulfate and naltrexone HCl) Extended-Release Capsules, 20 mg/0.8 mg, 30 mg/1.2 mg, 50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and 100 mg/4 mg | Alpharma Pharmaceuticals, LLC, 235 East 42nd St., New York, NY 10017. |
| NDA 022510 | Abstral (fentanyl) Sublingual Tablets,100 micrograms (mcg), 200 mcg, 300 mcg, 400 mcg, 600 mcg, and 800 mcg | Sentynl Therapeutics, Inc., 420 Stevens Ave., Suite 200, Solana Beach, CA 92075. |
| NDA 050641 | Monodox (doxycycline monohydrate) Capsules, EQ 50mg base, EQ 75mg base, and EQ 100mg base | Aqua Pharmaceuticals, LLC, 707 Eagleview Blvd., Suite 200, Exton, PA 19341. |
Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of June 15, 2020. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on June 15, 2020 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Dated: May 11, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.